Back to results
US 11,447,830 B2Granted
Gene signatures to predict drug response in cancer
AssigneeBoard of Regents, The University of Texas System
InventorsShiaw-Yih Lin, Daniel McGrail, Gordon Mills
Life of this patent
Estimating the term…
Abstract
Methods for identifying and treating cancers that are DNA repair, such as homologous recombination (HR) repair, defective or sensitive to PARP inhibitors or platinum-based therapy. In some aspects, DNA repair, such as HR repair, defective cancers are treated with a PARP inhibitor therapy or cisplatin. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.
Claims30
A method of treating a cancer in a subject comprising:
- (a) determining the expression levels of at least genes ZNF880, CAPN13, LYAR, and NPM3 from the group consisting of SNX10, ECI2, DBN1, TNFRSF10B, NPM3, CATSPER1, PRMT3, FAM216A, LYAR, NOP16, THG1L, LOC439949, TMA16, GEMIN4, HAUS6, SFXN4, SAAL1, NUP160, ESD, TSEN15, KIAA1704, HSPA4, SFXN1, NAT10, C11orf48, TSEN2, HEATR2, GEMIN5, IMPDH2, NOC3L, ERLIN1, C1QBP, EIF3M, MTHFD1L, MTX3, MRPS27, PPRC1, TCOF1, IDE, RNF2, WDR75, NAA15, DDX21, RARS, ALG8, BOLA3, EARS2, FAF2, MRPL42, ATIC, NUP37, RPL36, GNB2L1, NPBWR1, GALNTL5, LOC729173, LOC441461, KALRN, ADCY2, MTHFR, MS4A7, RNF186, IRF4, WBSCR17, CLEC7A, WDTC1, PRKG2, OSTalpha, DUSP18, LOC100652843, FAIM2, TNNI2, SEZ6, LOC285556, KCNQ1, KLF8, VPS13D, NR0B2, TMEM86A, DCAF5, SOS2, CAPN9, RIPK3, TPRXL, CELF4, ATP6V1E1, ZBTB7C, CATSPERB, CAPN13, MMEL1, ELF5, C2orf54, DVL3, SIRT2, LOC641518, IL12RB2, CBFA2T2, LINC00518, OSBPL2, SH3GLB1, CHMP4B, HSD11B2, ACVR1C, TMEM61, DLL3, CXCL17, SLC44A4, RNF183, KLK8, RIIAD1, ATP7A, GJB1, BCAS1, SCGN, TTC3, IGSF11, LOC440335, LOC645591, C4orf3, LRRC31, ADAM12, BHLHE41, RNASE1, PPP1R3B, LOC100505989, CAPN8, C2CD4A, CHGA, ERBB2, NELL1, FAM174B, CALML5, TSC22D3, C9orf152, KLK6, MB, ST6GALNAC1, SFTA2, MUC1, SETBP1, SCG3, PRUNE2, SSPN, CEACAM5, TMEM45B, MAFB, and ZNF880 in a sample comprising cancer cells from said subject;
- (b) identifying the subject as having a PARP inhibitor sensitive cancer by calculating a signature score from the expression levels of the genes, wherein a positive signature score identifies the subject as having a PARP inhibitor sensitive cancer;
- and
- (c) administering an effective amount of a PARP inhibitor to said subject identified to have a PARP inhibitor sensitive cancer.
1 more element
Dependencies are inferred from the claim text.